Quantitative analysis for Forte Biosciences, Inc. (FBRX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (19.0) (grade F). 30 signals analyzed (25 differentiated alt-data).
FBRX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-21 | $34.82 | $32.74 | $32.84 |
| 2026-05-01 | $28.37 | $26.10 | $28.19 |
| 2026-05-13 | $24.70 | $23.24 | $24.66 |
| 2026-05-26 | $22.48 | $21.38 | $21.94 |
| 2026-06-05 | $16.70 | $15.71 | $16.52 |
| 2026-06-17 | $17.90 | $17.17 | $17.59 |
| 2026-06-30 | $22.39 | $20.41 | $21.25 |
| 2026-07-13 | $44.37 | $40.11 | $44.12 |
| 2026-07-23 | $62.46 | $54.26 | $59.70 |
| 2026-08-04 | $76.75 | $76.51 | $76.56 |
| 2026-08-14 | $76.87 | $76.82 | $76.83 |
| 2026-08-26 | $77.00 | $76.96 | $76.99 |
How Forte Biosciences, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| MGNX | MacroGenics, Inc. | $283M | — |
| CCCC | C4 Therapeutics, Inc. | $272M | — |
| ACIU | AC Immune S.A. | $294M | — |
| SLN | Silence Therapeutics plc | $295M | — |
View all Health Care stocks by valuation and signals →
Forte Biosciences, Inc. (FBRX) scores Strong Sell (19.0), and the composite conceals a 86-point disagreement between its dimensions. It is strongest on competitive moat at 93 and valuation at 72, and weakest on technicals at 7. A stock can carry competitive moat that high while technicals sits at 7; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 93 |
| valuation | 72 |
| earnings quality | 51 |
| analyst consensus | 45 |
| technicals | 7 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Forte Biosciences, Inc. (FBRX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/FBRX"><img src="https://stoquant.com/badge/FBRX.svg" alt="Forte Biosciences, Inc. (FBRX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.